scholarly journals Treatment with oxygen-ozone therapy in hemodialysis patients

Ozone Therapy ◽  
2019 ◽  
Vol 4 (2) ◽  
Author(s):  
Giuseppe Bonforte ◽  
Hilary Riva ◽  
Olivier Giannini ◽  
Brenno Balestra
Keyword(s):  
Pain Perception ◽  
Clinical Signs ◽  
Complete Healing ◽  
Limb Amputation ◽  
Successful Outcome ◽  
Secondary Amyloidosis ◽  
Ozone Therapy ◽  
Group 2 ◽  
Peripheral Arterial ◽  
Group 1

Peripheral arterial disease and secondary amyloidosis account for significant morbidity and mortality among uremic patients. Several papers demonstrated the beneficial effects of ozone therapy in the treatment of vascular and orthopaedic diseases. The aim of this paper is to study these effects among hemodialysed patients with severe complications. Seventy-five hemodialysed patients were studied. Sixty patients suffered from peripheral arterial occlusive disease. Twenty-three of them underwent previous unilateral lower limb amputation (Group 1). Fifteen subjects had remarkable joint pain due to a2-microglobulin deposition (Group 2). All patients were treated with analgesic therapy. The Italian Society for Oxygen-Ozone Therapy (SIOOT) protocols were applied: the patients received major O3 autohemotherapy, subcutaneous ozone infusion and body exposure to oxygen/ozone mixture by bagging. A questionnaire was submitted to the patients at the beginning and at the end of ozone therapy for the individual assessment of treatment efficacy. Complete healing of the ischemic ulcers was obtained in many patients. Eight-eight percent of the patients reported a subjective successful outcome after ozone therapy. Both Group 1 and Group 2 subjects reported a significant decrease in pain perception. The use of analgesic drugs was reduced in 78% of them and 72% got a normal sleep/wake cycle. An enhancement in physical activity was reported by 67% of the subjects. Ozone therapy improves hemodialysed patients’ quality of life reducing bone pain perception and attenuating clinical signs of peripheral vascular disease.

scholarly journals Efficacy of Anesthetic Agents to Delay Pain Onset After Periodontal Surgery

2011 ◽  
Vol 58 (2) ◽  
pp. 57-60 ◽  
Author(s):  
Joao Paulo Steffens ◽  
Márcia Thaís Pochapski ◽  
Fábio André Santos ◽  
Gibson Luiz Pilatti
Keyword(s):  
Postoperative Pain ◽  
Pain Intensity ◽  
Pain Perception ◽  
Clinical Signs ◽  
Periodontal Surgery ◽  
Anesthetic Agents ◽  
Parallel Group ◽  
Group 2 ◽  
Double Blinded ◽  
Group 1

Abstract The aim of this study was to evaluate the influence of 2 anesthetic agents on patients' postoperative pain perception after periodontal surgery. For this parallel-group, double-blinded, randomized clinical trial, 36 open flap debridement surgeries were performed on patients who presented with periodontal disease with clinical signs of inflammation after nonsurgical treatment on at least 1 quadrant. Patients were allocated to 1 of the following groups: group 1, 2% lidocaine with 1 ∶ 100,000 epinephrine; group 2, 2% mepivacaine with 1 ∶ 100,000 norepinephrine. Pain intensity was assessed using the visual analog scale during the first 8 hours after surgery. All patients received 750-mg acetaminophen tablets, which they were instructed to take as a rescue medication if necessary. The results demonstrated that postoperative pain intensity was statistically lower in group 2 than in group 1 at the 1-, 2-, and 3-hour periods after surgery, although the pain intensity for all groups could be considered mild. In conclusion, patients in both groups reported similar mild pain after periodontal surgery.

scholarly journals Management of surgical wound dehiscence by oxygen-ozone therapy in a FIV-positive cat – a case report

2020 ◽  
Vol 89 (2) ◽  
pp. 189-194
Author(s):  
Călin Cosmin Repciuc ◽  
Corina Gina Toma ◽  
Ciprian Andrei Ober ◽  
Liviu Ioan Oana
Keyword(s):  
Case Report ◽  
Wound Dehiscence ◽  
Complete Healing ◽  
Limb Amputation ◽  
X Rays ◽  
Surgical Wound ◽  
Ozone Therapy ◽  
Contraction Phase ◽  
Surgical Wound Dehiscence ◽  
Low Efficiency

Patients infected with the feline immunodeficiency virus (FIV) are frequently victims of postoperative wound dehiscence due to low efficiency of the immune system that predisposes to delayed scaring and epithelization processes. This case report aimed to describe the successful use of medical ozone in the treatment of a dehisced wound in a feline patient that presented this type of FIV-associated complication. Here we present a case of a 12-year-old, mixed-breed, male, FIV-positive cat with purulent arthritis affecting the shoulder, elbow, and the carpal joints with subsequent periostitis and arthrogryposis affecting the right forelimb. After a thorough investigation (clinical examination, X-rays) it was decided that limb amputation would be the proper choice. The surgical wound did not tend to heal, followed by rejection of the suture material, skin necrosis, and wound dehiscence. After 13 days following the surgery with allopathic treatment and no improvement, oxygen-ozone-therapy was started. Clinically, oxygen-ozone therapy showed significant results after the first session: borders of the wound got into the contraction phase, got attached to the underlying tissues, and exudates were significantly diminished. The therapy continued every 2 days showing improved blood perfusion of the affected area and a visible advancement of the contraction phase daily with complete healing in 1.5 months.

scholarly journals Impact of renal dysfunction on the management and outcome of acute heart failure: results from the French prospective, multicentre, DeFSSICA survey

BMJ Open ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. e022776 ◽  
Author(s):  
Dominique Dos Reis ◽  
Laurie Fraticelli ◽  
Adrien Bassand ◽  
Stéphane Manzo-Silberman ◽  
Nicolas Peschanski ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Renal Dysfunction ◽  
Acute Heart Failure ◽  
Clinical Signs ◽  
Academic Community ◽  
Close Monitoring ◽  
Early Assessment ◽  
Group 2 ◽  
Group 1

ObjectivesCardiorenal syndrome (CRS) is the combination of acute heart failure syndrome (AHF) and renal dysfunction (creatinine clearance (CrCl) ≤60 mL/min). Real-life data were used to compare the management and outcome of AHF with and without renal dysfunction.DesignProspective, multicentre.SettingTwenty-six academic, community and regional hospitals in France.Participants507 patients with AHF were assessed in two groups according to renal function: group 1 (patients with CRS (CrCl ≤60 mL/min): n=335) and group 2 (patients with AHF with normal renal function (CrCl >60 mL/min): n=172).ResultsDifferences were observed (group 1 vs group 2) at admission for the incidence of chronic heart failure (56.42% vs 47.67%), use of furosemide (60.9% vs 52.91%), insulin (15.52% vs 9.3%) and amiodarone (14.33% vs 4.65%); additionally, more patients in group 1 carried a defibrillator (4.78% vs 0%), had ≥2 hospitalisations in the last year (15.52% vs 5.81%) and were under the care of a cardiologist (72.24% vs 61.63%). Clinical signs were broadly similar in each group. Brain-type natriuretic peptide (BNP) and BNP prohormone were higher in group 1 than group 2 (1157.5 vs 534 ng/L and 5120 vs 2513 ng/mL), and more patients in group 1 were positive for troponin (58.2% vs 44.19%), had cardiomegaly (51.04% vs 37.21%) and interstitial opacities (60.3% vs 47.67%). The only difference in emergency treatment was the use of nitrates, (higher in group 1 (21.9% vs 12.21%)). In-hospital mortality and the percentage of patients still hospitalised after 30 days were similar between groups, but the median stay was longer in group 1 (8 days vs 6 days).ConclusionsRenal impairment in AHF should not limit the use of loop diuretics and/or vasodilators, but early assessment of pulmonary congestion and close monitoring of the efficacy of conventional therapies is encouraged to allow rapid and appropriate implementation of alternative therapies if necessary.

scholarly journals Use of a GnRH synthetic analog (buserelin) for estrous induction in female dogs

2018 ◽  
Vol 70 (3) ◽  
pp. 656-660
Author(s):  
R.S. Rezende ◽  
D. Eurides ◽  
C.P. Barbosa ◽  
M.S. Lacerda ◽  
R.L. Sampaio ◽  
...  
Keyword(s):  
Pregnancy Rate ◽  
Single Injection ◽  
Clinical Signs ◽  
Synthetic Analog ◽  
Intramuscular Injections ◽  
Group 2 ◽  
Group 1

ABSTRACT The aim of this study was to evaluate the effectiveness of a GnRH synthetic analog, as an estrous inducer in female dogs when administered during the anestrous phase, and to evaluate the pregnancy rate achieved through natural copulation. For this purpose, ten female dogs of different breeds were used. The subjects received buserelin by intramuscular injections at a dose of 2,1mcg when female dogs weighed up to 10kg (Group 1) and of 4,2mcg when the dogs weighed above 10kg (Group 2). Of the ten subjects, only three presented estrus after a single injection of buserelin: two dogs from Group 1 and one dog from Group 2 on average 7±1.29 days. The remaining seven dogs were given a second dose of buserelin, equal to the first administration. Of these, three belonged to Group 1 and four to Group 2. Four of these dogs exhibited clinical signs of estrus within, on average 9±7.3 days from the second injection. The seven female dogs that did enter estrus were fertilized successfully through natural copulation. The administration of buserelin was effective in inducing estrus in female dogs during the anestrous phase, with a maximum of two administrations.

scholarly journals Efficacy of Whole Cell Inactivated Vibrio harveyi Vaccine against Vibriosis in a Marine Red Hybrid Tilapia (Oreochromis niloticus × O. mossambicus) Model

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 734
Author(s):  
Nadirah Abu Nor ◽  
Mohd Zamri-Saad ◽  
Ina-Salwany Md Yasin ◽  
Annas Salleh ◽  
Farina Mustaffa-Kamal ◽  
...  
Keyword(s):  
Vibrio Harveyi ◽  
Clinical Signs ◽  
Economic Losses ◽  
Enzyme Linked Immunosorbent Assay ◽  
Skin Mucus ◽  
Fish Diseases ◽  
Group 2 ◽  
Adverse Environmental Conditions ◽  
And Control ◽  
Group 1

Vibrio harveyi causes vibriosis in various commercial marine fish species. The infection leads to significant economic losses for aquaculture farms, and vaccination is an alternative approach for the prevention and control of fish diseases for aquaculture sustainability. This study describes the use of formalin-killed Vibrio harveyi (FKVh) strain Vh1 as a vaccine candidate to stimulate innate and adaptive immunities against vibriosis in a marine red hybrid tilapia model. Tilapia are fast growing; cheap; resistant to diseases; and tolerant to adverse environmental conditions of fresh water, brackish water, and marine water and because of these advantages, marine red hybrid tilapia is a suitable candidate as a model to study fish diseases and vaccinations against vibriosis. A total of 180 healthy red hybrid tilapias were gradually adapted to the marine environment before being divided into two groups, with 90 fish in each group and were kept in triplicate with 30 fish per tank. Group 1 was vaccinated intraperitoneally with 100 µL of FKVh on week 0, and a booster dose was similarly administered on week 2. Group 2 was similarly injected with PBS. Skin mucus, serum, and gut lavage were collected weekly for enzyme-linked immunosorbent assay (ELISA) and a lysozyme activity assay from a total of 30 fish of each group. On week 4, the remaining 60 fish of Groups 1 and 2 were challenged with 108 cfu/fish of live Vibrio harveyi. The clinical signs were monitored while the survival rate was recorded for 48 h post-challenge. Vaccination with FKVh resulted in a significantly (p < 0.05) higher rate of survival (87%) compared to the control (20%). The IgM antibody titer and lysozyme activities of Group 1 were significantly (p < 0.05) higher than the unvaccinated Groups 2 in most weeks throughout the experiment. Therefore, the intraperitoneal exposure of marine red hybrid tilapia to killed V. harveyi enhanced the resistance and antibody response of the fish against vibriosis.

Multicenter, Randomized, Comparative Cost-effectiveness Study Comparing 0, 1, and 2 Diagnostic Medial Branch (Facet Joint Nerve) Block Treatment Paradigms before Lumbar Facet Radiofrequency Denervation

2010 ◽  
Vol 113 (2) ◽  
pp. 395-405 ◽  
Author(s):  
Steven P. Cohen ◽  
Kayode A. Williams ◽  
Connie Kurihara ◽  
Conner Nguyen ◽  
Cynthia Shields ◽  
...  
Keyword(s):  
Positive Response ◽  
The United States ◽  
Successful Outcome ◽  
Medial Branch ◽  
Cost Effective Treatment ◽  
Pain Clinics ◽  
Radiofrequency Denervation ◽  
Diagnostic Block ◽  
Group 2 ◽  
Group 1

Background Among patients presenting with axial low back pain, facet arthropathy accounts for approximately 10-15% of cases. Facet interventions are the second most frequently performed procedures in pain clinics across the United States. Currently, there are no uniformly accepted criteria regarding how best to select patients for radiofrequency denervation. Methods A randomized, multicenter study was performed in 151 subjects with suspected lumbar facetogenic pain comparing three treatment paradigms. Group 0 received radiofrequency denervation based solely on clinical findings; group 1 underwent denervation contingent on a positive response to a single diagnostic block; and group 2 proceeded to denervation only if they obtained a positive response to comparative blocks done with lidocaine and bupivacaine. A positive outcome was predesignated as &gt; or =50% pain relief coupled with a positive global perceived effect persisting for 3 months. Results In group 0, 17 patients (33%) obtained a successful outcome at 3 months versus eight patients (16%) in group 1 and 11 (22%) patients in group 2. Denervation success rates in groups 0, 1, and 2 were 33, 39, and 64%, respectively. Pain scores and functional capacity were significantly lower at 3 months but not at 1 month in group 2 subjects who proceeded to denervation compared with patients in groups 0 and 1. The costs per successful treatment in groups 0, 1, and 2 were $6,286, $17,142, and $15,241, respectively. Conclusions Using current reimbursement scales, these findings suggest that proceeding to radiofrequency denervation without a diagnostic block is the most cost-effective treatment paradigm.

scholarly journals The Clinicopathological Evaluations of the Efficacy of Incorporation of Amantadine Hydrochloride in the Treatment of West African Dwarf Goats Experimentally Infected with Peste des Petits Ruminants Virus

2019 ◽  
Vol 11 (4) ◽  
pp. 379-386
Author(s):  
Iniobong C.I. UGOCHUKWU ◽  
Sunday I. IDOKO ◽  
Jacinta N. OMEKE ◽  
Chioma I. ANEKE ◽  
Nuhu A. SANI ◽  
...  
Keyword(s):  
Clinical Signs ◽  
West African ◽  
Peste Des Petits Ruminants ◽  
Treatment Groups ◽  
West African Dwarf ◽  
West African Dwarf Goats ◽  
Group 3 ◽  
Group 2 ◽  
Dwarf Goats ◽  
Group 1

Peste des petits ruminants poses a major threat to the development of small ruminant production. The objective of this study was to determine the comparative efficacy of amantadine hydrochloride (HCl), oxytetracycline long acting (LA) and levamisole in West African dwarf (WAD) goats experimentally infected with PPR. In addition to the presence of the characteristic clinical signs, complement ELISA and haem agglutination inhibition (HI) tests were used to confirm PPR infection in the West African dwarf goats, then treatment was instituted in the different groups namely, group 1 which was treated with amantadine HCl orally, oxytetracycline LA intramuscularly (IM) and levamisole per os. Group 2 was treated with oxytetracycline LA IM and levamisole. Group 3 was treated with levamisole while group 4 served as untreated control. The physiological parameters namely rectal temperature, pulse rate and respiratory rates of the different groups were recorded. The mortality rates in the different treatment groups were also recorded. The respiratory rates of the WAD goats increased as the infection progressed, but the increase was not significant (P>0.05). The treatment helped reduce the respiratory rates in the treated WAD. The rectal temperatures of all the animals in the different treatment groups increased only slightly as the infection progressed and was not significant (P>0.05). The percentage mortalities were 0% in Group 1, 25% in the Group 2, 50% in the treated group 3 and highest (75%) in the untreated group respectively. In conclusion, incorporation of specific antiviral agents like amantadine hydrochloride in the treatment regimen with oxytetracycline and levamisole particularly during the early stages of the infection can reduce morbidity and mortality of the disease to the barest minimum.

scholarly journals Endothelial function in men with type 2 diabetes without clinical signs of cardiovascular disease

2016 ◽  
Vol 19 (5) ◽  
pp. 383-387 ◽  
Author(s):  
Irina Alexandrovna Khripun ◽  
Sergey Vladislavovich Vorobyev ◽  
Maxim Nikolaevich Morgunov ◽  
Michail Iosifovich Kogan
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Endothelial Function ◽  
Reactive Hyperemia ◽  
Clinical Signs ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Group 2 ◽  
Group 1

Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular disease that is based on endothelial dysfunction (ED). Currently, conventional diagnostic methods are unreliable, especially at early stages of disease.Aims. The aim of this work was to assess endothelial function in men with T2DM without clinical signs of cardiovascular disease.Materials and methods. The study included 100 patients (mean age, 54.3 ± 5.3 years) with a T2DM duration of less than 10 years and without signs of cardiovascular disease. The patients were divided into two groups: group 1 consisted of 60 patients with a T2DM duration of less than five years. Group 2 included 40 men with a history of diabetes between 5 and 10 years. Endothelial function was assessed by the levels of nitric oxide (NO), endothelial NO synthase type 3 (eNOS3), ICAM-1, VCAM-1, E-selectin, P-selectin, resistin and C-reactive protein and the arterial vasoreactivity of the brachial artery (BA) using the D. Celermajer method.Results. Results revealed decreases in levels of both eNOS3 by 2.5 fold (P = 0.0005) and NO by 1.9 fold (P = 0.043) in group 2 patients, compared to those in group 1 patients. When the duration of diabetes was greater than five years, levels of VCAM-1, resistin and C-reactive protein increased by 12.1% (P = 0.048), 62% (P = 0.01) and 45.6%, respectively. Additionally, the time until maximal BA vasodilatation during reactive hyperemia was observed to be higher in group 2 [105 (90; 180) seconds] than those in group 1 [90 (60; 120) seconds].Conclusions. Biochemical and imaging signs of ED begin to appear in the first five years of T2DM, long before clinical manifestations. The earliest symptoms are decreases in eNOS3 and NO levels, increases in VCAM-1 and resistin concentrations and increased time until maximal BA vasodilatation during reactive hyperemia.

scholarly journals Clinical value of soluble suppression of tumourigenicity 2 (sST2) in addition to NTproBNP measurements in a general cardiac outpatient population

2021 ◽  
Author(s):  
Camille Ammann ◽  
Christophe Wyss ◽  
Oliver Gämperli ◽  
Peter Martin Wenaweser ◽  
Roberto Corti ◽  
...  
Keyword(s):  
Heart Failure ◽  
Independent Predictor ◽  
Clinical Signs ◽  
Left Atrial Volume ◽  
Atrial Volume ◽  
Clinical Value ◽  
Group 4 ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

BACKGROUND AND AIMS: The soluble form of suppression of tumourigenicity 2 (sST2), a recently introduced biomarker, is a strong and NTproBNP-independent predictor of outcome in heart failure patients. This study sought to evaluate the added clinical value of sST2 in addition to NTproBNP in a heterogeneous cardiac outpatient population. METHODS: A total of 297 all-comer patients visiting the outpatient clinic of Heart Clinic Zurich, Switzerland, from January to December 2018 were included. Patients were divided into four groups depending on their sST2 and NTproBNP levels: group 1 (n = 91, 30.6% of all patients) with normal levels of both biomarkers, group 2 (n = 41, 13.8%) with isolated elevation of sST2 but normal NTproBNP, group 3 (n = 97, 32.7%) with elevated NTproBNP but normal sST2 levels, and group 4 (n = 68, 22.9%) with elevation of both biomarkers. Differences between groups, Spearman’s correlations and linear and multiple regression analysis for sST2 were calculated. RESULTS: The median age was 74 ± 19 years and 41.8% were women. NTproBNP levels continuously increased across the groups (medians in pg/ml: group 1 123.0, group 2 152.0, group 3 990.0 and group 4 2610.0), whereas sST2 levels did not (medians in ng/ml: 28.7, 58.9, 28.4 and 63.7 for groups 1 to 4, respectively). In patients with normal NTproBNP (groups 1 and 2), elevation of sST2 (group 2) was associated with significantly higher rates of coronary artery disease, peripheral vascular disease and renal dysfunction. In patients with elevated NTproBNP (groups 3 and 4), the additional elevation of sST2 (group 4) was associated with clinical signs of heart failure, higher EuroScore II and worse left ventricular ejection fraction (LVEF group 3 58.0% vs group 4 53.3%, p = 0.022). Correlation of sST2 was overall weak and weaker than of NTproBNP with most clinical variables. Soluble ST2 significantly correlated with EuroScore II (R = 0.280), kidney function (R = −0.259), C-reactive protein (R = 0.248), right ventricular function (R = 0.213) and left atrial volume (R = 0.199), all p ≤0.001. In multiple regression analysis, left atrial volume was the strongest independent predictor of sST2 elevation (p = 0.002). CONCLUSION: In this all-comer cardiology population, the added clinical value of sST2 measurements in addition to NTproBNP was small. In patients with elevated NTproBNP, the simultaneous elevation of sST2 was associated with clinical signs of heart failure. Soluble ST2 measurements could thus be beneficial in patients with uncertain signs of heart failure and confounding factors for NTproBNP elevation. Surprisingly, this study found elevated sST2 levels in a substantial number of a patients with normal NTproBNP levels, pointing to an additional pathway of sST2 elevation independent of heart failure.

scholarly journals The Conundrum of Ventricular Dilatations Following Decompressive Craniectomy: Is Ventriculoperitoneal Shunt, The Only Panacea?

2018 ◽  
Vol 09 (02) ◽  
pp. 232-239 ◽  
Author(s):  
Raja K. Kutty ◽  
Sunilkumar Balakrishnan Sreemathyamma ◽  
Jyothish Sivanandapanicker ◽  
Prasanth Asher ◽  
Rajmohan Bhanu Prabhakar ◽  
...  
Keyword(s):  
Decompressive Craniectomy ◽  
Ventriculoperitoneal Shunt ◽  
Clinical Status ◽  
Clinical Signs ◽  
Outpatient Basis ◽  
Radiological Criteria ◽  
Shunt Group ◽  
Csf Diversion ◽  
Group 2 ◽  
Group 1

ABSTRACTIntroduction:Ventriculomegaly and hydrocephalus (HCP) are sometimes a bewildering sequela of decompressive craniectomy (DC). The distinguishing criteria between both are less well defined. Majority of the studies quoted in the literature have defined HCP radiologically, rather than considering the clinical status of the patient. Accordingly, these patients have been treated with permanent cerebrospinal fluid (CSF) diversion procedures. We hypothesize that asymptomatic ventriculomegaly following DC should undergo aspiration with cranioplasty and be followed up regularly. Materials and Methods: All patients with post-DC who were scheduled for cranioplasty and satisfied the radiological criteria for HCP were included. These patients were categorized into two groups. Group 1 included ventriculomegaly with clinical signs attributable to HCP and Group 2 constituted ventriculomegaly but no clinical signs attributable to HCP. All patients in Group 1 underwent ventriculoperitoneal shunt followed by cranioplasty, whereas all patients in Group 2 underwent cranioplasty along with simultaneous ventriculostomy and temporary aspiration of the lateral ventricle. All patients were regularly followed as the outpatient basis. Results: There were 21 patients who developed ventriculomegaly following DC. There were 10 patients in Group 1 and 11 patients in Group 2. The average duration of follow-up was from 6 months to 2 years. Two patients in the shunt group - (group 1) had over drainage and required revision. One patient in aspiration group - (group 2) required permanent CSF diversion. Conclusion: Cranioplasty with aspiration is a viable option in selected group of patients in whom there is ventriculomegaly but no signs or symptoms attributable to HCP.

Sign in / Sign up

Export Citation Format

Share Document